Oncology Pricing and Reimbursement Analysis

Service Features

• Over 10,000 approved and R&D drugs for oncology and supportive care, covering a global pipeline of pricing, approval, and cost information for medicines in Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States
  • Fifty-five sets of data per drug from Phase I through to approval, including:
  • Average annual cost per drug in each of the approved indications for any marketed drug, taking into account the price, dosing, average duration of use, and presentation of the drug in each market
  • Reimbursement restrictions, including guidance from institutions such as the United Kingdom's National Institutes of Clinical Health and Excellence (NICE), the German Institute for Quality and Efficiency in Healthcare (IQWiG), France's Transparency Commission, Italy's Agenzia Italiana del Farmaco (AIFA), and United States' National Comprehensive Cancer Network (NCCN)
  • Ex-manufacturing prices
  • Clinical trial design, endpoints, and results
  • Approval information, including impending approval dates, expected upcoming filings, new indications, and orphan drug/fast-track designations
  • Descriptions for all drugs, including analysis of mechanisms of action for experimental or marketed drugs
  • Licensing status, indicating whether a drug is available for licensing or if an agreement is already in place
• Daily updates

• Tracks all major events in oncology, including regulatory submissions, price changes, major conferences, clinical data, and mergers and acquisitions related to cancer area, drug class, and regulatory profiles
• A Weekly Oncology Milestones Bulletin, summarizing every update made throughout the week to the database and including an editorial perspective on the week's key themes and developments

• Exclusive information for all significant cancer areas (e.g., breast cancer, acute myeloid leukaemia, and supportive care), including standard of care, major new drug approvals, market data, and significant research and development trends
• Overview of all drug classes related to cancer, including older areas (e.g., plant alkaloids), newer areas (e.g., TK inhibitors, HDAC inhibitors), and non-approved classes (e.g., HSP90 inhibitors)
• Overview of all the major oncology-related regulatory mechanisms and pricing developments